data. Costs and benefits were discounted at 5% per annum as per Hungarian guidelines. RESULTS: With reference to the ATTAIN trial, and assuming a treatment duration of 1 year and 10 years time horizon, abatacept was cost-effective compared to MTX, yielding 0.57 additional QALY at an additional cost of 2.03 million HUF with an incremental cost-effectiveness ratio of 3.6 million HUF/QALY based on a societal perspective. From the Hungarian health insurance perspective, the incremental costeffectiveness ratio was 4.4 million HUF/QALY gained. Compared to cycled anti-TNFs, abatacept was dominant (more effective and overall less costly), with a QALY gain of 0.48 and estimated savings of HUF 731113. From the Hungarian health insurance perspective, the savings were 479 815 HUF. The results are robust to extensive sensitivity analyses. CONCLUSIONS:
To evaluate the effect of golimumab (GLM) treatment on time lost from work in rheumatoid arthritis (RA) patients. METHODS: The effect of GLM on time lost from work was evaluated in three multicenter, randomized, double-blind, placebo (PBO)-controlled RA studies (GO-BEFORE, GO-FORWARD, and GO-AFTER). Data from patients receiving GLM or PBO with or without methotrexate (MTX) were included. GLM SC injections of 50 mg or 100 mg were administered q4wks. Analyses were pooled to increase the power to detect a difference between treatment groups. Time lost from work was collected through a questionnaire at baseline and q8wks through wk24. Time lost from work was summarized cumulatively through wk16 and wk24 and compared between groups using an ANOVA on van der Waerden normal scores. The analysis was limited to patients <65 years of age and employed full-time at baseline. The proportion of patients reporting no days lost from work in the GLM +/-MTX group compared with PBO +/-MTX was calculated and compared between groups using chi-square test. RESULTS: There were significant differences in time lost from work (days) for patients treated with GLM +/-MTX through wk16 and wk24 compared with PBO +/-MTX. At wk24, the PBO +/-MTX group had lost on average 6.9 Ϯ 19.7 days compared with 5.0 Ϯ 19.4 days for the combined GLM +/-MTX group, a difference of 1.9 days (p = 0.004). At wk 24, the 75th percentile for the combined GLM +/-MTX group was 1.000 day (range 0-180) compared with 3.000 days (range 0-120) for the PBO +/-MTX group. A significantly higher proportion of patients in the combined GLM +/-MTX group reported no time (days) lost from work compared with PBO +/-MTX (73.1% vs. 60.7%; p = 0.002). CONCLUSIONS: GLM +/-MTX significantly reduced time lost from work for RA patients compared with PBO +/-MTX. A significantly higher proportion of patients in the GLM group reported no time lost from work compared with PBO +/-MTX.
PMS44 PARAMEDICAL OR ALTERNATIVE TREATMENTS AND ASSOCIATED COSTS FOR THE MANAGEMENT OF FIBROMYALGIA IN FRANCE
Maugars Y 1 , Lamotte M 2 ,Van Vlaenderen I 3 , Le Lay K 4 , Taieb C 4 1 Hotel Dieu, Nantes, France, 2 IMS Health, Brussels, Belgium, 3 IMS Health Belgium, Brussels, Belgium, 4 Pierre Fabre, Boulogne, France OBJECTIVES: To describe the multidisciplinary outpatient management of fibromyalgia and the paramedical resources and alternative treatments used in France, METHODS: A French expert panel, involving 33 general practitioners (GP) and 27 rheumatologists, was asked to describe their prescribed paramedical care and other alternative treatments in fibromyalgia patients, by means of a questionnaire covering a period of four years before diagnosis to four plus years after diagnosis, with 1-year intervals. Average reported prescriptions were calculated. Costs were calculated by multiplying prescribed resource use with corresponding French unit costs (€; 2007; societal perspective). RESULTS: Paramedical resource use and other alternative treatments increase substantially as from year from four years untill the first year after diagnosis, and slightly decrease in the subsequent years. In the first year after fibromyalgia diagnosis, 20% of the panel prescribes various food supplements in 59% of their patients (average duration varying between 8 and 52 weeks); 93% prescribes physiotherapy in 63% of their patients (average duration of 14 weeks); 57% prescribes thermal baths in 23% of their patients (3 weeks); 55% prescribes acupuncture in 30% of their patients (14 weeks); 48% prescribes chiropractor therapy in 28% of their patients (8 weeks); 55% prescribes relaxation therapy in 24% of patients (17 weeks); 37% prescribes psychoanalysis in 21% of patients (28 weeks); 20% prescribes hypnotherapy in 16% of patients (9 weeks); 8% prescribes biofeedback in 16% of patients (20 weeks). The average cost from a societal perspective is estimated at €387 per patient per year, ranging from €265 before diagnosis (4 year period), over €678 in the year following diagnosis, towards €453 in the period after diagnosis (3 year period). CONCLUSIONS: Paramedical and alternative treatment of fibromyalgia represents 387 euros per patient and per year from the societal perspective. Resource use and costs steadily increase till the year following diagnosis and decline afterwards. 
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